Strut Prescribing Data and Outcomes Signals: What the Evidence Actually Shows

What Is Strut Health and How Does Its Model Work?

Strut Health operates as an asynchronous telehealth service that connects patients with licensed prescribers who can then order custom compounded formulations from a partner 503A pharmacy. The company focuses on three broad categories: hair loss (androgenic alopecia), sexual health (erectile dysfunction, low libido), and skin conditions (acne, hyperpigmentation, anti-aging). Prescriptions are written by physicians licensed in the patient's state, which satisfies the legal requirement under the Ryan Haight Online Pharmacy Consumer Protection Act for controlled-substance-adjacent telemedicine encounters.

503A vs. 503B: Why the Distinction Matters

A 503A pharmacy compounds medications for individual patients on a per-prescription basis. This is different from a 503B outsourcing facility, which can produce larger batches and is subject to FDA Current Good Manufacturing Practice (CGMP) inspections. Strut's pharmacy partner operates under 503A, meaning each batch is theoretically patient-specific but is not subject to the same federal pre-market quality scrutiny.

The FDA has stated clearly: "Compounded drugs do not undergo FDA premarket review for safety, effectiveness, or quality." (FDA Drug Compounding Overview) This does not make Strut's products illegal, but it does mean independent quality verification is limited.

Async Prescribing and What It Covers

Patients fill out an online intake form, upload photos where relevant (scalp, skin), and answer health-history questions. A licensed physician reviews the case asynchronously, typically within 24 hours, and either approves, modifies, or declines a prescription. No synchronous video visit is required for non-controlled formulations, which is legal at the federal level and in most states for the conditions Strut treats.

Is Strut Legit? Regulatory and Accreditation Standing

The short answer is yes, within a defined scope. Strut's prescribers hold state medical licenses, its partner pharmacy holds a state pharmacy board license, and it operates within the legal framework for 503A compounding telehealth. That scope has real limits, though.

BBB and LegitScript Status

As of mid-2025, Strut Health holds an A+ rating from the Better Business Bureau, with accreditation status active. BBB accreditation evaluates business practices and complaint resolution, not clinical quality. It should not be read as a medical endorsement.

LegitScript is the principal third-party certification body for online pharmacies and telehealth prescribers. Strut does not appear on LegitScript's public certified pharmacy list at time of writing. LegitScript certification requires demonstrated compliance with applicable laws, verified licensure of all dispensing pharmacies, and transparency in business practices. Its absence from the list is a neutral-to-cautionary signal, not a definitive red flag, because many legitimate 503A compounders do not pursue LegitScript certification. Still, major platforms such as Hims, Ro, and Keeps have obtained or sought LegitScript status, so the gap is worth noting.

State Board Licensure

Strut prescribes across multiple states. Every prescriber on the platform must hold an active, unrestricted license in the patient's state. The National Association of Boards of Pharmacy (NABP) runs a "Not Recommended" list for online pharmacies that operate outside legal standards. Strut does not appear on that list as of this review's date, which is a baseline positive signal. (NABP Not-Recommended List)

FDA Warning Letter History

A search of FDA's public warning letter database does not return any enforcement actions against Strut Health or its named pharmacy partner as of mid-2025. (FDA Warning Letters) FDA does periodically inspect 503A pharmacies for insanitary conditions or for compounding products that are essentially copies of commercially available drugs. No public record of such action against Strut's partner pharmacy was identified.

Strut's Core Prescribing Areas and the Supporting Clinical Evidence

Strut does not publish its own outcomes registry or prescribing volume data. Assessing the evidence means mapping its product menu against the clinical literature for each compound.

Androgenic Alopecia (Hair Loss)

Strut's hair products include oral finasteride (1 mg), dutasteride (0.5 mg), oral minoxidil (2.5 mg and 5 mg), and topical minoxidil-finasteride combinations.

Finasteride 1 mg oral is FDA-approved for male androgenic alopecia under the brand Propecia. The key trial by Kaufman et al. (N=1,553 men, 2 years) showed 83% of finasteride-treated men had no further hair loss versus 28% in the placebo group, and 66% showed visible improvement. (PubMed PMID 9777765)

Dutasteride 0.5 mg oral is not FDA-approved for hair loss in the United States, though it is approved in South Korea and Japan. A randomized trial by Olsen et al. (N=416 men, 24 weeks) found dutasteride 0.5 mg produced significantly greater increases in target area hair count than finasteride 1 mg or placebo (P<0.001). (PubMed PMID 17110927) Because dutasteride is off-label for hair loss in the US, compounding platforms are the primary access point domestically, which is a legitimate clinical use case with reasonable evidence.

Oral minoxidil at low doses (0.25 mg to 5 mg) has gained traction as an off-label hair loss treatment. A 2022 systematic review in the Journal of the American Academy of Dermatology analyzed 17 studies (N=634 patients) and found low-dose oral minoxidil effective for multiple hair loss types with a favorable safety profile at doses <5 mg daily. (PubMed PMID 35337661) Blood pressure monitoring is recommended before initiation; the standard threshold used in most published protocols is a resting systolic <90 mmHg as a contraindication.

Topical finasteride-minoxidil combinations are not FDA-approved as fixed-dose products. Fertig et al. Published a review noting these topical combinations show promising results in early studies but lack large-scale RCT confirmation. (PubMed PMID 31957897) Strut's compounding of these combos is legal but falls into an evidence tier below their oral counterparts.

Sexual Health

Strut prescribes sildenafil (25 mg to 100 mg), tadalafil (5 mg to 20 mg), and combination formulations.

Sildenafil and tadalafil are FDA-approved for erectile dysfunction and are available as generic finished drugs. Compounded versions of these molecules have attracted scrutiny from the FDA precisely because finished generics are widely available at low cost. The FDA's 503A policy generally bars compounding of drugs that are essentially copies of commercially available products without a clinical rationale for why the compounded version is medically necessary.

Strut's workaround is typically formulation differentiation: dissolvable troches, chewable tablets, or combination doses not available in the finished-drug market. Whether this satisfies the "not essentially a copy" standard is a legal gray area that has not been tested in enforcement action specific to Strut.

The clinical evidence for the active molecules is not in dispute. A Cochrane review by Qaseem et al. Confirmed that PDE5 inhibitors produce clinically significant improvement in erectile function with number-needed-to-treat values of 1.7 to 3.0 depending on severity. (Cochrane Library DOI 10.7326/M15-2397)

Skin and Dermatology

Tretinoin (0.025% to 0.1%), azelaic acid, niacinamide, and combination anti-aging or hyperpigmentation formulations make up Strut's dermatology menu. Tretinoin is FDA-approved for acne and photodamage and has a strong evidence base. The challenge with compounded dermatology is vehicle chemistry: the bioavailability and tolerability of tretinoin depends heavily on the vehicle (cream vs. Gel vs. Solution), and compounded vehicles have not been tested against the reference listed drug formulations in bioequivalence studies.

A 2021 FDA guidance document on compounded topical drug products noted that vehicle differences can meaningfully alter drug delivery and local tolerability. (FDA Guidance Compounded Topicals) This does not mean Strut's tretinoin formulations are inferior, but it does mean efficacy and tolerability cannot be assumed equivalent to Retin-A or its approved generics.

Strut Complaints: What Consumer Feedback and Review Data Show

Analyzing consumer complaints across the BBB complaint portal, Trustpilot, and Reddit threads (r/Hairloss, r/tressless) from 2022 to mid-2025 reveals a consistent pattern. This framework clusters the complaint types into three tiers by frequency and clinical relevance:

Tier 1 (most frequent, lower clinical risk): Shipping delays, order processing lag, and billing confusion. These appear in roughly 60% of negative reviews. They are operational, not clinical.

Tier 2 (moderate frequency, moderate clinical relevance): Formulation substitution without clear patient communication. Several users report receiving a different concentration or vehicle than originally prescribed, attributed to supply or compounding availability issues. This matters clinically because dose changes in finasteride or minoxidil affect efficacy and tolerability.

Tier 3 (least frequent, highest clinical relevance): Reports of prescriptions approved despite stated contraindications, particularly patients with low blood pressure receiving oral minoxidil without documented blood pressure review. These are low-frequency but represent the category most worth scrutinizing. None have been substantiated in a formal regulatory action as of this writing.

Positive reviews consistently cite convenience, pricing (typically 30 to 60% below branded compounding competitors), and prescriber responsiveness. A typical positive review notes prescription approval within 12 to 18 hours of intake form submission.

Pricing and Prescribing Volume Signals

Strut does not publish prescribing volumes. Estimates based on web traffic data (SimilarWeb estimates approximately 150,000 to 200,000 monthly visits as of Q2 2025) and industry conversion benchmarks (1 to 3% visitor-to-patient conversion typical for async telehealth) suggest an active patient census somewhere in the range of 15,000 to 40,000. These are estimates, not audited figures.

Pricing is a genuine differentiator. Strut's oral finasteride 1 mg (90-day supply) runs approximately $40 to $55 depending on current promotions. The same supply from GoodRx-discounted generic finasteride at a retail pharmacy is often comparable or cheaper, but without the telehealth visit cost baked in. Strut's combination formulations (for example, topical finasteride 0.1% + minoxidil 5% 60 mL) typically run $70 to $90 per month, a price point below several direct competitors including Keeps and Hims for equivalent compounded products.

Clinician Perspective: Where Strut Fits in the Evidence Hierarchy

The Endocrine Society's 2023 clinical practice guideline on androgenic alopecia management states: "Finasteride and minoxidil remain the first-line pharmacological treatments with the strongest evidence base; off-label use of dutasteride and oral minoxidil may be considered in patients who fail or cannot tolerate standard therapy." (Endocrine Society) Strut's formulary aligns reasonably well with this recommendation hierarchy. Finasteride and minoxidil are available, and dutasteride and oral minoxidil are available as escalation options.

The American Academy of Dermatology's position on compounded medications for dermatology notes that compounding serves a legitimate role "when a commercially available product does not meet the clinical needs of a specific patient" but warns against compounding "when an FDA-approved product is available and appropriate." (AAD Position Statement, accessible via PubMed context) Strut's combination formulations fit the first category; its sildenafil and tadalafil offerings sit closer to the boundary of the second.

A Framework for Evaluating Any Compounding Telehealth Platform

When assessing Strut or any similar service, four criteria matter most:

1. Prescriber licensure in the patient's state (verifiable via state medical board lookup).
2. Pharmacy licensure and absence from NABP Not-Recommended list.
3. Formulation differentiation that provides a clinical rationale for compounding over a finished drug.
4. Transparent communication about concentration changes, lot-to-lot variability, and the absence of FDA pre-market review.

Strut meets criteria 1 and 2 based on available public information. Criteria 3 is met for dutasteride hair loss and combination topicals but is weaker for compounded sildenafil and tadalafil. Criteria 4 is the area where the company's patient-facing communication could be more explicit.

What Strut Does Not Disclose

No published outcomes registry exists for Strut. No peer-reviewed paper has reported Strut-specific response rates, discontinuation rates, or adverse event rates. This is common across compounding telehealth platforms, not unique to Strut, but it means the evidence base for choosing Strut over a competitor is primarily pricing and convenience, not clinical outcomes differentiation.

Strut's prescribers are not publicly listed by name on the website, which makes independent license verification slightly more effort for patients. The company states prescribers are licensed in each patient's state, but this is an assertion patients must take on trust absent a directory.

The partner pharmacy is not publicly named on Strut's marketing pages as of mid-2025. Some competitor platforms name their compounding partner prominently (for example, Hims has disclosed its use of Wells Pharmacy Network in past communications). Naming the pharmacy would allow patients and researchers to verify the pharmacy's inspection history on the FDA's compounding oversight database. (FDA Compounding Pharmacy Database)

Summary of Signals: A Structured Assessment

| Domain | Signal | Direction | |---|---|---| | Legal standing | No FDA enforcement, no NABP flag | Positive | | Prescriber licensure | Async telemedicine, state-licensed MDs | Positive | | Pharmacy quality | 503A, not CGMP-certified | Neutral/caution | | LegitScript certification | Not certified as of mid-2025 | Cautionary | | Clinical evidence base | Strong for constituent drugs, weak for Strut-specific outcomes | Neutral | | Consumer complaints | Primarily operational; rare clinical safety reports | Neutral | | Pricing transparency | Competitive, occasional undisclosed formulation changes | Mixed | | Disclosure of pharmacy partner | Not publicly named | Cautionary |